These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22037582)

  • 1. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
    Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay.
    Muller BH; Savatier A; L'Hostis G; Costa N; Bossus M; Michel S; Ott C; Becquart L; Ruffion A; Stura EA; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):545-62. PubMed ID: 22019475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody.
    Ménez R; Michel S; Muller BH; Bossus M; Ducancel F; Jolivet-Reynaud C; Stura EA
    J Mol Biol; 2008 Feb; 376(4):1021-33. PubMed ID: 18187150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
    Tajiri M; Ohyama C; Wada Y
    Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
    Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
    Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
    Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
    Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
    Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.
    Sarrats A; Saldova R; Comet J; O'Donoghue N; de Llorens R; Rudd PM; Peracaula R
    OMICS; 2010 Aug; 14(4):465-74. PubMed ID: 20726802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural model for the prostate disease marker, human prostate-specific antigen.
    Villoutreix BO; Getzoff ED; Griffin JH
    Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification of human prostatic-specific antigen (hPSA) from seminal plasma by immunoaffinity chromatography using a monoclonal antibody anti total PSA.
    Pérez L; Zulueta O; Melchor A; Hernández L; López R; Cazanave J; Béquer D
    Hybridoma (Larchmt); 2011 Jun; 30(3):247-51. PubMed ID: 21707359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
    Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
    Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein.
    Corey E; Buhler KR; Vessella RL
    Urology; 1997 Oct; 50(4):567-71; discussion 571-2. PubMed ID: 9338733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.